Skip to search formSkip to main contentSkip to account menu

INK128

Known as: INK-128, TAK-228 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

BenzoxazolesPyrimidinesSapanisertib

Narrower (1)

MLN0128

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer…
Background: TAK-228 is an investigational, oral and highly selective ATP-competitive inhibitor of TORC1/2. Targeting the PI3K/AKT… 
2018
2018
Impact of immune suppressive agents on the BK‐Polyomavirus non coding control region
2016
2016
A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies
2016
2016
The mTOR Kinase Inhibitor INK128 Blunts Migration of Cultured Retinal Pigment Epithelial Cells.
Retinal pigment epithelium (RPE) cell migration in response to disease has been reported for age-related macular degeneration… 
2016
2016
INK128 Exhibits Synergy with Azoles against Exophiala spp. and Fusarium spp.
Infections of Exophiala spp. and Fusarium spp. are often chronic and recalcitrant. Systemic disseminations, which mostly occur in… 
2015
2015
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation
Effects of concurrent inhibition of mTORC1/2 and Bcl-2/Bcl-xL in human acute myeloid leukemia cells were examined. Tetracycline… 
2014
2014
The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
2012
2012
Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: INK128 is an orally bioavailable… 
2012
2012
Cancer Therapy : Preclinical Dual mTORC 1 / 2 and HER 2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER 2 Therapy
Purpose: The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that is refractory to anti-HER2 therapy… 
2012
2012
Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
626 Background: Downstream of the PI3K-AKT pathway, the mTOR has been shown to be essential effector in promoting cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)